MOUNTAIN VIEW, Calif., Aug. 7, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that, after more than a decade of service, Garrett A. Garrettson has resigned his seat on the IRIDEX Board of Directors.
President and CEO Will Moore said, "Garry's insight and guidance on matters of technology, capital markets and corporate governance were a constant and steadying force through some very eventful years at IRIDEX. On behalf of all the shareholders, we are grateful for his decade of commitment and oversight and wish him well as he sets off on his next set of ventures."
Dr. Garrettson served as a director of the Company since 2004 and served as Lead Independent Director and then Chairman of the Company's Board of Directors from January 2008 to September 2010. Dr. Garrettson is currently a principal of daVinci Capital Group, a private equity fund, and of G. Garrettson Consulting.
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The company maintains a deep commitment to the success of its customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through both direct and independent sales forces and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the company's website at http://www.iridex.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to changes at the Company as a result of Garry Garrettson's resignation, the Company's commitments to its customers and the technological superiority of the Company's products. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in the Company's Quarterly Report on Form 10-Q and the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2013, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
SOURCE IRIDEX Corporation